期刊
AMERICAN JOURNAL OF KIDNEY DISEASES
卷 54, 期 5, 页码 931-934出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2009.03.013
关键词
Deferasirox; Fanconi syndrome; iron; renal toxicity
Deferasirox is an innovative iron-chelating treatment. However, preliminary data have suggested that kidney toxicity may be a major issue in the management of patients receiving this drug. We report a case of Fanconi syndrome associated with acute renal insufficiency in a patient receiving deferasirox. The latter has to be added to the expanding list of drugs that may induce Fanconi syndrome. Careful monitoring of kidney function and markers of proximal tubular injury are mandatory in patients undergoing treatment with deferasirox. Am J Kidney Dis 54:931-934. (C) 2009 by the National Kidney Foundation, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据